Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study
- 370 Downloads
To prospectively explore the value of dynamic contrast-enhanced magnetic resonance imaging (DCE–MRI) in predicting the progression of enhancing lesions persisting after standard treatment in patients with surgically resected glioblastoma (GBM).
Forty-seven GBM patients, who underwent near-total tumorectomy followed by concurrent chemoradiation therapy (CCRT) with temozolomide (TMZ) between May 2014 and February 2016, were enrolled. Twenty-four patients were finally analyzed for measurable enhancing lesions persisting after standard treatment. DCE-MRI parameters were calculated at enhancing lesions. Mann–Whitney U tests and multivariable stepwise logistic regression were used to compare parameters between progression (n = 16) and non-progression (n = 8) groups.
Mean Ktrans and ve were significantly lower in progression than in non-progression (P = 0.037 and P = 0.037, respectively). The 5th percentile of the cumulative Ktrans histogram was also significantly lower in the progression than in non-progression group (P = 0.017). Mean ve was the only independent predictor of progression (P = 0.007), with a sensitivity of 100%, specificity of 63%, and an overall accuracy of 88% at a cut-off value of 0.873.
DCE-MRI may help predict the progression of enhancing lesions persisting after the completion of standard treatment in patients with surgically resected GBM, with mean ve serving as an independent predictor of progression.
• Enhancing lesions may persist after standard treatment in GBM patients.
• DCE-MRI may help predict the progression of the enhancing lesions.
• Mean Ktransand vewere lower in progression than in non-progression group.
• DCE-MRI may help identify patients requiring close follow-up after standard treatment.
• DCE-MRI may help plan treatment strategies for GBM patients.
KeywordsChemoradiotherapy Glioblastoma Magnetic resonance imaging Perfusion Progression
Arterial input function
Cerebral blood volume
Concurrent radiation therapy and chemotherapy
Fluid-attenuated inversion recovery sequence
Field of view
O6-Methylguanine DNA methyltransferase
Magnetization-prepared rapid acquisition gradient echo
Number of excitations
Response assessment in neuro-oncology
Receiver operating characteristic
Region of interest
- 8.Kim JH, Choi SH, Ryoo I et al (2014) Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. PLoS One 9, e113587CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Keith B, Johnson RS, Simon MC (2012) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9–22Google Scholar
- 38.Rischin D, Hicks RJ, Fisher R et al (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098–2104CrossRefPubMedGoogle Scholar
- 41.Jensen RL, Mumert ML, Gillespie DL, Kinney AY, Schabel MC, Salzman KL (2014) Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol 16:280–291CrossRefPubMedGoogle Scholar